Keisuke Koroki

599 total citations
17 papers, 89 citations indexed

About

Keisuke Koroki is a scholar working on Hepatology, Oncology and Cancer Research. According to data from OpenAlex, Keisuke Koroki has authored 17 papers receiving a total of 89 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 6 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Keisuke Koroki's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer Mechanisms and Therapy (3 papers). Keisuke Koroki is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer Mechanisms and Therapy (3 papers). Keisuke Koroki collaborates with scholars based in Japan, China and United States. Keisuke Koroki's co-authors include Hiroaki Kanzaki, Kazufumi Kobayashi, Tetsuhiro Chiba, Sadahisa Ogasawara, Naoya Kato, Masato Nakamura, Tomoko Saito, Soichiro Kiyono, Shingo Nakamoto and Naoya Kanogawa and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Keisuke Koroki

14 papers receiving 87 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keisuke Koroki Japan 5 58 28 27 20 16 17 89
Peter R. Galle Germany 5 63 1.1× 44 1.6× 16 0.6× 24 1.2× 13 0.8× 18 114
Yamil Alonso Lopez Chuken Mexico 3 84 1.4× 36 1.3× 21 0.8× 32 1.6× 12 0.8× 6 103
Susumu Maruta Japan 3 46 0.8× 21 0.8× 17 0.6× 11 0.6× 12 0.8× 6 79
Ann‐Shing Lee China 5 89 1.5× 38 1.4× 24 0.9× 24 1.2× 49 3.1× 7 118
Marta Piqué‐Gili United Kingdom 4 75 1.3× 19 0.7× 26 1.0× 54 2.7× 21 1.3× 4 125
Sam Khan United Kingdom 6 23 0.4× 20 0.7× 26 1.0× 31 1.6× 16 1.0× 18 96
Liqun Wu China 6 77 1.3× 29 1.0× 12 0.4× 31 1.6× 55 3.4× 13 117
J.F. Blanc France 5 76 1.3× 42 1.5× 17 0.6× 33 1.6× 18 1.1× 14 100
Riccardo Memeo Italy 4 39 0.7× 10 0.4× 28 1.0× 32 1.6× 35 2.2× 9 101

Countries citing papers authored by Keisuke Koroki

Since Specialization
Citations

This map shows the geographic impact of Keisuke Koroki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisuke Koroki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisuke Koroki more than expected).

Fields of papers citing papers by Keisuke Koroki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keisuke Koroki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisuke Koroki. The network helps show where Keisuke Koroki may publish in the future.

Co-authorship network of co-authors of Keisuke Koroki

This figure shows the co-authorship network connecting the top 25 collaborators of Keisuke Koroki. A scholar is included among the top collaborators of Keisuke Koroki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisuke Koroki. Keisuke Koroki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Miwa, Chihiro, Sadahisa Ogasawara, Tomomi Okubo, et al.. (2025). Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy. Cancer Medicine. 14(5). e70642–e70642. 1 indexed citations
2.
Koroki, Keisuke, Sadahisa Ogasawara, Miyuki Nakagawa, et al.. (2025). Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma. JHEP Reports. 7(10). 101509–101509.
3.
Ogasawara, Sadahisa, Keisuke Koroki, Hirokazu Makishima, et al.. (2024). Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.. Journal of Clinical Oncology. 42(3_suppl). 480–480.
4.
Koroki, Keisuke, Sadahisa Ogasawara, Chihiro Miwa, et al.. (2024). Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular Carcinoma. Liver Cancer. 14(3). 286–301.
5.
Ao, Junjie, Hiroaki Kanzaki, Masato Nakamura, et al.. (2024). Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis. American Journal of Physiology-Cell Physiology. 327(4). C1150–C1161. 2 indexed citations
6.
Mikata, Rintaro, Shiroh Isono, Sadahisa Ogasawara, et al.. (2023). Phase II study comparing nasal pressure monitoring with capnography during invasive endoscopic procedures: a single-center, single-arm trial. Scientific Reports. 13(1). 1265–1265. 1 indexed citations
7.
Kondo, Takayuki, Miyuki Nakagawa, Takamasa Ishino, et al.. (2023). Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients. Scientific Reports. 13(1). 11524–11524. 2 indexed citations
8.
Kondo, Takayuki, Keisuke Koroki, Hiroaki Kanzaki, et al.. (2022). Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS ONE. 17(1). e0261619–e0261619. 8 indexed citations
9.
Kanzaki, Hiroaki, Sadahisa Ogasawara, Naoto Fujita, et al.. (2022). Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.. Journal of Clinical Oncology. 40(4_suppl). 467–467. 2 indexed citations
10.
Ogasawara, Sadahisa, Keisuke Koroki, Hirokazu Makishima, et al.. (2022). Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.. Journal of Clinical Oncology. 40(4_suppl). TPS495–TPS495. 1 indexed citations
11.
Kobayashi, Kazufumi, Sadahisa Ogasawara, Yuya Seko, et al.. (2021). Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study.. Journal of Clinical Oncology. 39(3_suppl). 317–317. 1 indexed citations
12.
Ogasawara, Sadahisa, Keisuke Koroki, Hiroaki Kanzaki, et al.. (2021). Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver International. 42(9). 2055–2066. 15 indexed citations
13.
Maruyama, Hitoshi, Rintaro Mikata, Shin Yasui, et al.. (2021). Percutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic Tumor. Diagnostics. 11(3). 498–498. 5 indexed citations
14.
Koroki, Keisuke, Naoya Kanogawa, Susumu Maruta, et al.. (2021). Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 39(3_suppl). 278–278. 1 indexed citations
15.
Ogasawara, Sadahisa, Yoshihiko Ooka, Keisuke Koroki, et al.. (2020). Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology. 26(2). 155–162. 43 indexed citations
16.
Kanayama, Kengo, Tetsuhiro Chiba, Kazufumi Kobayashi, et al.. (2020). Long-term administration of Tolvaptan to patients with decompensated cirrhosis. International Journal of Medical Sciences. 17(7). 874–880. 5 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter R. Galle Breakdown of academic impact, for papers by Yamil Alonso Lopez Chuken Breakdown of academic impact, for papers by Susumu Maruta Breakdown of academic impact, for papers by Ann‐Shing Lee Breakdown of academic impact, for papers by Marta Piqué‐Gili Breakdown of academic impact, for papers by Sam Khan Breakdown of academic impact, for papers by Liqun Wu Breakdown of academic impact, for papers by J.F. Blanc Breakdown of academic impact, for papers by Riccardo Memeo
Rankless by CCL
2026